Upstream Bio UPB
Upstream Bio, Inc. · Nasdaq · Pharmaceutical Preparations
$2.98+6.81%close on Oct. 28, 2026 · volume 1.3M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 16, 2026 | Michael Gray CFO and COO | Sold | 853 | $5.49 | $4,683 |
| Sept. 16, 2026 | Allison Ambrose General Counsel | Sold | 485 | $5.49 | $2,663 |
| Sept. 16, 2026 | Aaron Deykin Chief Medical Officer | Sold | 895 | $5.49 | $4,914 |
| Sept. 16, 2026 | Everett Rand Sutherland Chief Executive Officer, director | Sold | 2,095 | $5.49 | $11,502 |
| Sept. 16, 2026 | Adam Houghton Chief Business Officer | Sold | 700 | $5.49 | $3,843 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 10 →Regulation FD disclosure · Other events · Financial statements and exhibits